FY2019 Earnings Estimate for Lexicon Pharmaceuticals, Inc. Issued By Wedbush (NASDAQ:LXRX)
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Analysts at Wedbush dropped their FY2019 earnings per share estimates for shares of Lexicon Pharmaceuticals in a research note issued to investors on Monday. Wedbush analyst L. Moussatos now anticipates that the biopharmaceutical company will post earnings of $0.76 per share for the year, down from their previous estimate of $0.82. Wedbush currently has a “Ourperform” rating and a $39.00 target price on the stock. Wedbush also issued estimates for Lexicon Pharmaceuticals’ FY2020 earnings at $3.12 EPS and FY2021 earnings at $4.83 EPS.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12. Lexicon Pharmaceuticals had a negative return on equity of 116.74% and a negative net margin of 290.87%. The company had revenue of $12 million during the quarter, compared to analysts’ expectations of $18.34 million. During the same quarter in the previous year, the firm earned ($0.37) EPS. Lexicon Pharmaceuticals’s revenue was down 40.3% on a year-over-year basis. TRADEMARK VIOLATION WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/08/08/fy2019-earnings-estimate-for-lexicon-pharmaceuticals-inc-issued-by-wedbush-nasdaqlxrx.html.
LXRX has been the topic of a number of other research reports. BidaskClub downgraded Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, June 29th. Zacks Investment Research upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. ValuEngine upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. HC Wainwright set a $27.00 price target on Lexicon Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, May 3rd. Finally, Cowen and Company restated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $27.00.
Lexicon Pharmaceuticals (NASDAQ LXRX) traded down 1.926% during trading on Tuesday, hitting $15.025. The stock had a trading volume of 429,311 shares. The stock’s market capitalization is $1.59 billion. Lexicon Pharmaceuticals has a 52 week low of $13.41 and a 52 week high of $19.62. The company has a 50-day moving average of $16.60 and a 200-day moving average of $15.38.
A number of hedge funds and other institutional investors have recently modified their holdings of LXRX. Highbridge Capital Management LLC purchased a new position in shares of Lexicon Pharmaceuticals during the first quarter valued at $7,813,000. Sector Gamma AS purchased a new position in shares of Lexicon Pharmaceuticals during the first quarter valued at $4,765,000. Wellington Management Group LLP increased its position in shares of Lexicon Pharmaceuticals by 11.1% in the first quarter. Wellington Management Group LLP now owns 279,874 shares of the biopharmaceutical company’s stock valued at $4,013,000 after buying an additional 27,964 shares in the last quarter. Teachers Advisors LLC increased its position in shares of Lexicon Pharmaceuticals by 34.4% in the fourth quarter. Teachers Advisors LLC now owns 106,890 shares of the biopharmaceutical company’s stock valued at $1,478,000 after buying an additional 27,378 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Lexicon Pharmaceuticals during the fourth quarter valued at $12,582,000.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.